The risk of weight gain — this is the most important concern for young women.

The teratogenic risk of valproate, including the association with neural tube defects and neurodevelopmental effects. The PMHNP should discuss contraception requirements, FDA labeling warnings, the need for pregnancy testing before initiation, and alternative mood stabilizers with more favorable reproductive safety profiles.

The need for therapeutic drug monitoring only — other risks can be discussed at follow-up.

No additional elements — standard informed consent covers all medications equally.